High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas

Gouji Toyokawa, Kazuki Takada, Tatsuro Okamoto, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Shinkichi Takamori, Takaki Akamine, Masakazu Katsura, Fumihiro Shoji, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Our objective is to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in emphysematous bullae (EB)-associated lung adenocarcinomas. Seventy patients (19.0%) were positive for PD-L1 expression. Thirty-six (44.4%) and 29 (58.0%) of 81 and 50 patients with EB and cancer adjoining EB, respectively, were positive for PD-L1 expression. EB-associated lung adenocarcinomas express PD-L1 protein more frequently than those without EB. Objective Emphysematous bullae (EB) are known to be associated with a high incidence of lung cancer; however, the reason for this has yet to be elucidated. The objective of the present study was to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in EB-associated lung adenocarcinomas. Patients and Methods A total of 369 patients with resected lung adenocarcinoma whose preoperative computed tomography findings were available for the examination of EB were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and EB-related adenocarcinomas. Results Among 369 patients, EB and cancer adjoining EB (Ca-ADJ) were identified in 81 (22.0%) and 50 (13.6%) patients, respectively. EB and Ca-ADJ were significantly associated with male gender, a smoking habit, a decreased forced expiratory volume in 1 second, a relatively higher tumor grade, advanced T status and stage, the presence of pleural and vessel invasion, invasive pathologic subtypes, and wild-type epidermal growth factor receptor. Seventy patients (19.0%) were positive for PD-L1 expression, whereas the remaining 299 patients (81.0%) were negative. Thirty-six (44.4%) and 29 (58.0%) of 81 and 50 patients with EB and Ca-ADJ, respectively, were positive for PD-L1 expression, which was shown to be significant by the Fisher exact test (P < .001 and P < .001, respectively). Among the 81 lung adenocarcinomas with EB, Ca-ADJ was significantly associated with PD-L1 expression (P = .021). In a multivariate analysis, the presence of Ca-ADJ was found to be an independent predictor of PD-L1 expression. Conclusions EB-associated lung adenocarcinomas express PD-L1 protein more frequently than those without EB.

Original languageEnglish
Pages (from-to)504-511.e1
JournalClinical Lung Cancer
Volume18
Issue number5
DOIs
Publication statusPublished - Sep 2017

Fingerprint

Blister
Ligands
Neoplasms
Adenocarcinoma of lung
Forced Expiratory Volume
Epidermal Growth Factor Receptor
Habits
Lung Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Toyokawa, G., Takada, K., Okamoto, T., Kozuma, Y., Matsubara, T., Haratake, N., ... Maehara, Y. (2017). High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas. Clinical Lung Cancer, 18(5), 504-511.e1. https://doi.org/10.1016/j.cllc.2016.11.011

High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas. / Toyokawa, Gouji; Takada, Kazuki; Okamoto, Tatsuro; Kozuma, Yuka; Matsubara, Taichi; Haratake, Naoki; Takamori, Shinkichi; Akamine, Takaki; Katsura, Masakazu; Shoji, Fumihiro; Oda, Yoshinao; Maehara, Yoshihiko.

In: Clinical Lung Cancer, Vol. 18, No. 5, 09.2017, p. 504-511.e1.

Research output: Contribution to journalArticle

Toyokawa, G, Takada, K, Okamoto, T, Kozuma, Y, Matsubara, T, Haratake, N, Takamori, S, Akamine, T, Katsura, M, Shoji, F, Oda, Y & Maehara, Y 2017, 'High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas', Clinical Lung Cancer, vol. 18, no. 5, pp. 504-511.e1. https://doi.org/10.1016/j.cllc.2016.11.011
Toyokawa, Gouji ; Takada, Kazuki ; Okamoto, Tatsuro ; Kozuma, Yuka ; Matsubara, Taichi ; Haratake, Naoki ; Takamori, Shinkichi ; Akamine, Takaki ; Katsura, Masakazu ; Shoji, Fumihiro ; Oda, Yoshinao ; Maehara, Yoshihiko. / High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas. In: Clinical Lung Cancer. 2017 ; Vol. 18, No. 5. pp. 504-511.e1.
@article{89fc3b48e4a34f9e8bebac6d0d5e4a99,
title = "High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas",
abstract = "Our objective is to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in emphysematous bullae (EB)-associated lung adenocarcinomas. Seventy patients (19.0{\%}) were positive for PD-L1 expression. Thirty-six (44.4{\%}) and 29 (58.0{\%}) of 81 and 50 patients with EB and cancer adjoining EB, respectively, were positive for PD-L1 expression. EB-associated lung adenocarcinomas express PD-L1 protein more frequently than those without EB. Objective Emphysematous bullae (EB) are known to be associated with a high incidence of lung cancer; however, the reason for this has yet to be elucidated. The objective of the present study was to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in EB-associated lung adenocarcinomas. Patients and Methods A total of 369 patients with resected lung adenocarcinoma whose preoperative computed tomography findings were available for the examination of EB were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and EB-related adenocarcinomas. Results Among 369 patients, EB and cancer adjoining EB (Ca-ADJ) were identified in 81 (22.0{\%}) and 50 (13.6{\%}) patients, respectively. EB and Ca-ADJ were significantly associated with male gender, a smoking habit, a decreased forced expiratory volume in 1 second, a relatively higher tumor grade, advanced T status and stage, the presence of pleural and vessel invasion, invasive pathologic subtypes, and wild-type epidermal growth factor receptor. Seventy patients (19.0{\%}) were positive for PD-L1 expression, whereas the remaining 299 patients (81.0{\%}) were negative. Thirty-six (44.4{\%}) and 29 (58.0{\%}) of 81 and 50 patients with EB and Ca-ADJ, respectively, were positive for PD-L1 expression, which was shown to be significant by the Fisher exact test (P < .001 and P < .001, respectively). Among the 81 lung adenocarcinomas with EB, Ca-ADJ was significantly associated with PD-L1 expression (P = .021). In a multivariate analysis, the presence of Ca-ADJ was found to be an independent predictor of PD-L1 expression. Conclusions EB-associated lung adenocarcinomas express PD-L1 protein more frequently than those without EB.",
author = "Gouji Toyokawa and Kazuki Takada and Tatsuro Okamoto and Yuka Kozuma and Taichi Matsubara and Naoki Haratake and Shinkichi Takamori and Takaki Akamine and Masakazu Katsura and Fumihiro Shoji and Yoshinao Oda and Yoshihiko Maehara",
year = "2017",
month = "9",
doi = "10.1016/j.cllc.2016.11.011",
language = "English",
volume = "18",
pages = "504--511.e1",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas

AU - Toyokawa, Gouji

AU - Takada, Kazuki

AU - Okamoto, Tatsuro

AU - Kozuma, Yuka

AU - Matsubara, Taichi

AU - Haratake, Naoki

AU - Takamori, Shinkichi

AU - Akamine, Takaki

AU - Katsura, Masakazu

AU - Shoji, Fumihiro

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2017/9

Y1 - 2017/9

N2 - Our objective is to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in emphysematous bullae (EB)-associated lung adenocarcinomas. Seventy patients (19.0%) were positive for PD-L1 expression. Thirty-six (44.4%) and 29 (58.0%) of 81 and 50 patients with EB and cancer adjoining EB, respectively, were positive for PD-L1 expression. EB-associated lung adenocarcinomas express PD-L1 protein more frequently than those without EB. Objective Emphysematous bullae (EB) are known to be associated with a high incidence of lung cancer; however, the reason for this has yet to be elucidated. The objective of the present study was to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in EB-associated lung adenocarcinomas. Patients and Methods A total of 369 patients with resected lung adenocarcinoma whose preoperative computed tomography findings were available for the examination of EB were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and EB-related adenocarcinomas. Results Among 369 patients, EB and cancer adjoining EB (Ca-ADJ) were identified in 81 (22.0%) and 50 (13.6%) patients, respectively. EB and Ca-ADJ were significantly associated with male gender, a smoking habit, a decreased forced expiratory volume in 1 second, a relatively higher tumor grade, advanced T status and stage, the presence of pleural and vessel invasion, invasive pathologic subtypes, and wild-type epidermal growth factor receptor. Seventy patients (19.0%) were positive for PD-L1 expression, whereas the remaining 299 patients (81.0%) were negative. Thirty-six (44.4%) and 29 (58.0%) of 81 and 50 patients with EB and Ca-ADJ, respectively, were positive for PD-L1 expression, which was shown to be significant by the Fisher exact test (P < .001 and P < .001, respectively). Among the 81 lung adenocarcinomas with EB, Ca-ADJ was significantly associated with PD-L1 expression (P = .021). In a multivariate analysis, the presence of Ca-ADJ was found to be an independent predictor of PD-L1 expression. Conclusions EB-associated lung adenocarcinomas express PD-L1 protein more frequently than those without EB.

AB - Our objective is to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in emphysematous bullae (EB)-associated lung adenocarcinomas. Seventy patients (19.0%) were positive for PD-L1 expression. Thirty-six (44.4%) and 29 (58.0%) of 81 and 50 patients with EB and cancer adjoining EB, respectively, were positive for PD-L1 expression. EB-associated lung adenocarcinomas express PD-L1 protein more frequently than those without EB. Objective Emphysematous bullae (EB) are known to be associated with a high incidence of lung cancer; however, the reason for this has yet to be elucidated. The objective of the present study was to clarify the prevalence of programmed death-ligand-1 (PD-L1) expression in EB-associated lung adenocarcinomas. Patients and Methods A total of 369 patients with resected lung adenocarcinoma whose preoperative computed tomography findings were available for the examination of EB were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and EB-related adenocarcinomas. Results Among 369 patients, EB and cancer adjoining EB (Ca-ADJ) were identified in 81 (22.0%) and 50 (13.6%) patients, respectively. EB and Ca-ADJ were significantly associated with male gender, a smoking habit, a decreased forced expiratory volume in 1 second, a relatively higher tumor grade, advanced T status and stage, the presence of pleural and vessel invasion, invasive pathologic subtypes, and wild-type epidermal growth factor receptor. Seventy patients (19.0%) were positive for PD-L1 expression, whereas the remaining 299 patients (81.0%) were negative. Thirty-six (44.4%) and 29 (58.0%) of 81 and 50 patients with EB and Ca-ADJ, respectively, were positive for PD-L1 expression, which was shown to be significant by the Fisher exact test (P < .001 and P < .001, respectively). Among the 81 lung adenocarcinomas with EB, Ca-ADJ was significantly associated with PD-L1 expression (P = .021). In a multivariate analysis, the presence of Ca-ADJ was found to be an independent predictor of PD-L1 expression. Conclusions EB-associated lung adenocarcinomas express PD-L1 protein more frequently than those without EB.

UR - http://www.scopus.com/inward/record.url?scp=85009260474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009260474&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2016.11.011

DO - 10.1016/j.cllc.2016.11.011

M3 - Article

C2 - 28038981

AN - SCOPUS:85009260474

VL - 18

SP - 504-511.e1

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 5

ER -